Phase 2
Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will present data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene’s DC vaccine during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
Here’s a roundup of some of the top clinical trial news from the previous week.
Primary analysis of L-MIND trial of tafasitamab (MOR208) plus lenalidomide in relapsed or refractory (r/r) DLBCL confirms overall strong data reported previously from this trial
MorphoSys AG today announced results from the primary analysis (cut-off date November 30, 2018) of the ongoing single-arm phase 2 clinical trial known as L-MIND.
“ALS is a disease you really want to make a difference in,” Toby Ferguson Biogen’s senior medical director for Neuromuscular Research and Early Development told BioSpace.
Yamo Pharmaceuticals, LLC announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD.
InflaRx today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in patients with ANCA-associated vasculitis (AAV) (NCT03895801).
In its first-quarter financial report, Solid Biosciences updated on its Phase I/II IGNITE DMD clinical trial. The progress was marred by adverse events.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
PRESS RELEASES